GlassScriptPhysician profile
Dwight M Williams
NPI 1619930591
$3,841.05
in general payments reported to CMS, 2019-2025
33 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $236 · 2021: $797 · 2022: $446 · 2023: $666 · 2024: $671 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $815.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $512.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $479.91 | 2021-2025 | Qulipta |
| Novo Nordisk INC | $368.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $219.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.58 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $168.42 | 2023-2025 | Rexulti |
| Amgen INC. | $123.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $101.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.83 | 2021-2022 | |
| Allergan, INC. | $87.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.13 | 2022-2023 | |
| Eisai INC. | $67.67 | 2021-2024 | |
| Astellas Pharma US INC | $61.50 | 2021-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $59.42 | 2019-2024 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.31 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.50 | 2019-2023 | Eliquis |
| Nestle Healthcare Nutrition INC. | $34.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $33.13 | 2020 | |
| Genentech USA, INC. | $28.52 | 2019 | |
| Sanofi Pasteur INC. | $26.67 | 2019-2021 | |
| Genzyme Corporation | $24.37 | 2025 | |
| Tris Pharma INC | $17.30 | 2025 | Dyanavel Xr |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2024 | Dupixent |
| Sumitomo Pharma America, INC. | $16.27 | 2023 | Gemtesa |
| Aimmune Therapeutics, INC. | $16.12 | 2025 | Zenpep |
| Horizon Therapeutics Plc | $15.45 | 2021 | |
| Amarin Pharma, INC. | $15.32 | 2020 | |
| Boston Scientific Corporation | $12.62 | 2022 | |
| Esperion Therapeutics, INC. | $12.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.73 | 2022 | |
| Lilly USA, LLC | $11.27 | 2021 | |
| Corium, LLC | $9.46 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.